BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OTULFI (ustekinumab-aauz) by Fresenius Kabi is interleukin-12 antagonists [moa]. First approved in 2024.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OTULFI (ustekinumab-aauz) is a monoclonal antibody that antagonizes interleukin-12, a key cytokine driver of immune-mediated inflammatory diseases. This is a biosimilar referencing the originator ustekinumab (Stelara), expanding treatment access for patients with conditions like psoriasis, psoriatic arthritis, and Crohn's disease. The IL-12 antagonism mechanism reduces pathogenic Th1 and Th17 cell differentiation.
Growth
Early-stage biosimilar in growth phase with moderate competitive pressure (30) suggests expanding commercial infrastructure and team-building opportunities for newly approved product.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Fresenius Kabi is hiring 1 role related to this product
Worked on OTULFI at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.